Martina Landschoof Skrede

  • Research technologist
  • +47 23 02 78 23

Publications 2022

Silwal-Pandit L, Stålberg SM, Henrik J. Johansson, Georgios Mermelekas, Lothe IMB, Skrede ML, Dalsgaard AM, Nebdal D, Helland, Lingjærde OC, Labori KJ, Skålhegg BS, Janne Lehtiö, Kure EH (2022)
Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome
Cancer Res Commun, 2 (6), 434-446
DOI 10.1158/2767-9764.CRC-21-0100, PublikaID 411

Publications 2016

Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Cancer Res, 76 (17), 5092-102
DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532

Publications 2015

Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH (2015)
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
Mol Oncol, 10 (2), 303-16
DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090

Publications 2014

Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH (2014)
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
Mol Oncol, 9 (4), 758-71
DOI 10.1016/j.molonc.2014.12.002, PubMed 25579086

Publications 2012

Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2012)
Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
PLoS One, 7 (4), e34150
DOI 10.1371/journal.pone.0034150, PubMed 22529906

Hetland TE, Kaern J, Skrede M, Sandstad B, Trope C, Davidson B, Florenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother. Pharmacol., 69 (5), 1307-1314
DOI 10.1007/s00280-012-1835-9

Publications 2011

Hamfjord J, Stangeland AM, Skrede ML, Tveit KM, Ikdahl T, Kure EH (2011)
Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations
Diagn Mol Pathol, 20 (3), 158-65
DOI 10.1097/PDM.0b013e31820b49e2, PubMed 21817902

Publications 2008

Odlo K, Hentzen J, dit Chabert JF, Ducki S, Gani OA, Sylte I, Skrede M, Flørenes VA, Hansen TV (2008)
1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
Bioorg Med Chem, 16 (9), 4829-38
DOI 10.1016/j.bmc.2008.03.049, PubMed 18396050

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602

Publications 2007

Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R (2007)
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781

Davidson B, Skrede M, Silins I, Shih IeM, Trope CG, Flørenes VA (2007)
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260

Publications 2006

Kleinberg L, Flørenes VA, Skrede M, Dong HP, Nielsen S, McMaster MT, Nesland JM, Shih IeM, Davidson B (2006)
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch, 449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284

Publications 2005

Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA (2005)
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302

Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropè CG, Kristensen GB, Nesland JM, Børresen-Dale AL (2005)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759

Publications 2004

Flørenes VA, Skrede M, Jørgensen K, Nesland JM (2004)
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res, 14 (3), 173-81
DOI 10.1097/01.cmr.0000129576.49313.26, PubMed 15179185

Publications 2003

Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA (2003)
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393

Publications 1998

Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjaerg L, Dørum A, Møller P, Weber BL, Børresen-Dale AL (1998)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening
Hum Mutat, 11 (2), 166-74
DOI 10.1002/(SICI)1098-1004(1998)11:2<166::AID-HUMU10>3.0.CO;2-X, PubMed 9482581

Publications 1997

Andersen TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Eeles R, Tveit KM, Johnston SRD, Dowsett M, Olsen AO, Moller P, Stratton MR, BorresenDale AL (1997)
Screening for ESR mutations in breast and ovarian cancer patients
Hum. Mutat., 9 (6), 531-536

Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Møller P, Stratton MR, Børresen-Dale AL (1997)
Screening for ESR mutations in breast and ovarian cancer patients
Hum Mutat, 9 (6), 531-6
DOI 10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.0.CO;2-4, PubMed 9195227

Publications 1996

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O (1996)
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme
Cancer Res, 56 (23), 5490-8
PubMed 8968106

Publications 1995

Heimdal K, Andersen TI, Skrede M, Fosså SD, Berg K, Børresen AL (1995)
Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population
Cancer Epidemiol Biomarkers Prev, 4 (2), 123-6
PubMed 7742719

Publications 1994

Hum. Genet., 94 (6), 665-670

Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Børresen AL (1994)
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility
Hum Genet, 94 (6), 665-70
DOI 10.1007/BF00206961, PubMed 7989041

Flørenes VA, Oyjord T, Holm R, Skrede M, Børresen AL, Nesland JM, Fodstad O (1994)
TP53 allele loss, mutations and expression in malignant melanoma
Br J Cancer, 69 (2), 253-9
DOI 10.1038/bjc.1994.48, PubMed 7905277

Publications 1993

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL (1993)
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712

Publications 1991

Borstad E, Skrede M, Rud T (1991)
Failure to predict and attempts to explain urinary stress incontinence following vaginal repair in continent women by using a modified lateral urethrocystography
Acta Obstet Gynecol Scand, 70 (6), 501-6
DOI 10.3109/00016349109007168, PubMed 1842676

Publications 1989

Ottestad L, Tveit KM, Hannisdal E, Skrede M, Nesland JM, Gundersen S, Pihl A (1989)
Colony forming ability of human breast carcinomas: lack of prognostic significance
Br J Cancer, 60 (2), 216-9
DOI 10.1038/bjc.1989.254, PubMed 2765368

Page visits: 7661